柏柏林通过诱导铁亡来抑制前列腺癌的进展:来自网络药理学的证据
Peiliang Zou1, Shenghai Li, Qixiong He
1School of Clinical Medicine, Zhaoqing Medical College, Zhaoqing, Guangdong, China.
Anti-cancer drugs
|January 14, 2025
概括
柏柏林通过影响与铁亡相关的基因,显示出治疗前列腺癌的潜力. 这项研究确定了关键的基因和通路,体外结果证实了柏柏林的存在.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学 是一个学科.
- 计算生物学 计算生物学
背景情况:
- 柏柏林在前列腺癌中的作用,特别是关于铁亡的作用,仍然不清楚.
- 前列腺癌是一个重大的健康问题,需要新的治疗策略.
研究的目的:
- 通过网络药理学研究贝贝林在前列腺癌中与铁亡相关的机制.
- 确定贝贝林的关键标和涉及前列腺癌进展的途径.
主要方法:
- 网络药理学的方法是整合多个数据库 (Genecard,TCM系统药理学,瑞士目标预测).
- 识别共同的目标和枢纽基因,然后进行丰富分析 (基因本体学,KEGG途径).
- 对LNCaP和PC3前列腺癌细胞系的分子对接模拟和体外研究.
主要成果:
- 确定了17个常见的目标和10个枢纽基因 (例如,CCNB1,CDK1,AURKA,AR,TYMS,SCD).
- 丰富分析揭示了重要的基因本体学术语和KEGG途径.
- 柏柏林在体外抑制细胞增殖和下调关键基因 (TYMS,CCNB1,AURKA,CDK1,SCD),对AR和ICAM1产生细胞特异性影响.
结论:
- 柏柏林通过调节与铁亡相关的基因,显示出抑制前列腺癌进展的潜力.
- 确定了枢纽基因和通路,为进一步研究柏柏林的治疗应用提供了基础.
- 柏柏林对AR和ICAM1的独特影响表明细胞特异性治疗潜力.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Protein Networks
3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
Electron Transport Chain: Complex I and II
10.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.9K


